Markus Ketteler1, Geoffrey A Block2, Pieter Evenepoel3, Masafumi Fukagawa4, Charles A Herzog5, Linda McCann6, Sharon M Moe7, Rukshana Shroff8, Marcello A Tonelli9, Nigel D Toussaint10, Marc G Vervloet11, Mary B Leonard12. 1. Klinikum Coburg, Coburg, Germany, and University of Split School of Medicine, Split, Croatia (M.K.). 2. Denver Nephrology, Denver, Colorado (G.A.B.). 3. University Hospitals Leuven, Leuven, Belgium (P.E.). 4. Tokai University School of Medicine, Isehara, Japan (M.F.). 5. Hennepin County Medical Center and University of Minnesota, Minneapolis, Minnesota (C.A.H.). 6. Eagle, Idaho (L.M.). 7. Indiana University School of Medicine and Roudebush Veterans Affairs Medical Center, Indianapolis, Indiana (S.M.M.). 8. Great Ormond Street Hospital for Children, NHS Foundation Trust, London, United Kingdom (R.S.). 9. University of Calgary, Calgary, Alberta, Canada (M.A.T.). 10. The Royal Melbourne Hospital, University of Melbourne, Melbourne, Victoria, Australia (N.D.T.). 11. VU University Medical Center Amsterdam, Amsterdam, the Netherlands (M.G.V.). 12. Stanford University School of Medicine, Stanford, California (M.B.L.).
Abstract
Description: The Kidney Disease: Improving Global Outcomes (KDIGO) 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) is a selective update of the prior CKD-MBD guideline published in 2009. The guideline update and the original publication are intended to assist practitioners caring for adults with CKD and those receiving long-term dialysis. Methods: Development of the guideline update followed an explicit process of evidence review and appraisal. The approach adopted by the Work Group and the evidence review team was based on systematic reviews of relevant trials, appraisal of the quality of the evidence, and rating of the strength of recommendations according to the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach. Searches of the English-language literature were conducted through September 2015 and were supplemented with targeted searches through February 2017. Final modification of the guidelines was informed by a public review process involving numerous stakeholders, including patients, subject matter experts, and industry and national organizations. Recommendations: The update process resulted in the revision of 15 recommendations. This synopsis focuses primarily on recommendations for diagnosis of and testing for CKD-MBD and treatment of CKD-MBD that emphasizes decreasing phosphate levels, maintaining calcium levels, and addressing elevated parathyroid hormone levels in adults with CKD stage G3a to G5 and those receiving dialysis. Key elements include basing treatment on trends in laboratory values rather than a single abnormal result and being cautious to avoid hypercalcemia when treating secondary hyperparathyroidism.
Description: The Kidney Disease: Improving Global Outcomes (KDIGO) 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) is a selective update of the prior CKD-MBD guideline published in 2009. The guideline update and the original publication are intended to assist practitioners caring for adults with CKD and those receiving long-term dialysis. Methods: Development of the guideline update followed an explicit process of evidence review and appraisal. The approach adopted by the Work Group and the evidence review team was based on systematic reviews of relevant trials, appraisal of the quality of the evidence, and rating of the strength of recommendations according to the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach. Searches of the English-language literature were conducted through September 2015 and were supplemented with targeted searches through February 2017. Final modification of the guidelines was informed by a public review process involving numerous stakeholders, including patients, subject matter experts, and industry and national organizations. Recommendations: The update process resulted in the revision of 15 recommendations. This synopsis focuses primarily on recommendations for diagnosis of and testing for CKD-MBD and treatment of CKD-MBD that emphasizes decreasing phosphate levels, maintaining calcium levels, and addressing elevated parathyroid hormone levels in adults with CKD stage G3a to G5 and those receiving dialysis. Key elements include basing treatment on trends in laboratory values rather than a single abnormal result and being cautious to avoid hypercalcemia when treating secondary hyperparathyroidism.
Authors: Charles Ginsberg; Leila R Zelnick; Geoffrey A Block; Glenn M Chertow; Michel Chonchol; Andrew Hoofnagle; Bryan Kestenbaum; Ian H de Boer Journal: Nephrol Dial Transplant Date: 2020-04-01 Impact factor: 5.992
Authors: Elizabeth A Swallow; Mohammad W Aref; Corinne E Metzger; Spencer Sacks; Demi R Lehmkuhler; Neal Chen; Max A Hammond; Paul R Territo; Thomas L Nickolas; Sharon M Moe; Matthew R Allen Journal: Bone Date: 2019-07-09 Impact factor: 4.398
Authors: Annabel Biruete; Kathleen M Hill Gallant; Stephen R Lindemann; Gretchen N Wiese; Neal X Chen; Sharon M Moe Journal: J Ren Nutr Date: 2019-03-04 Impact factor: 3.655